Aurinia Pharmaceuticals (NASDAQ:AUPH) PT Raised to $30.00

Share on StockTwits

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) had its target price upped by Cantor Fitzgerald from $24.00 to $30.00 in a report released on Thursday morning, The Fly reports.

Several other research firms have also weighed in on AUPH. Oppenheimer upped their price target on Aurinia Pharmaceuticals from $14.00 to $22.00 in a research report on Thursday. Bloom Burton restated a buy rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. ValuEngine cut Aurinia Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, October 10th. Zacks Investment Research raised Aurinia Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, November 28th. Finally, Citigroup began coverage on Aurinia Pharmaceuticals in a report on Monday, September 9th. They issued an outperform rating and a $14.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Aurinia Pharmaceuticals currently has an average rating of Buy and a consensus target price of $18.46.

NASDAQ AUPH opened at $15.44 on Thursday. The firm’s 50 day moving average price is $6.08 and its two-hundred day moving average price is $6.03. Aurinia Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $17.48. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -20.32 and a beta of 1.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, November 14th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. On average, equities research analysts expect that Aurinia Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Aurinia Pharmaceuticals by 3.1% in the second quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after acquiring an additional 28,129 shares during the last quarter. Toronto Dominion Bank boosted its position in Aurinia Pharmaceuticals by 26.3% during the second quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,575 shares during the last quarter. A.R.T. Advisors LLC grew its stake in Aurinia Pharmaceuticals by 44.9% in the second quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 5,700 shares in the last quarter. SG Americas Securities LLC purchased a new position in Aurinia Pharmaceuticals in the third quarter valued at about $246,000. Finally, Benjamin F. Edwards & Company Inc. grew its stake in Aurinia Pharmaceuticals by 42.9% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 3,000 shares in the last quarter. 32.06% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: High-Yield Dividend Stocks

The Fly

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.